ArticleFrontiers in medicine2026
Case Report: A case of focal segmental glomerulosclerosis in Wilson's disease induced by penicillamine.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wilson's disease (WD) is a hereditary disorder that impairs copper metabolism. Both WD and its treatment with penicillamine are associated with renal impairment. We report a case of penicillamine-induced podocytopathy with pathological findings of early-stage focal segmental glomerulosclerosis (FSGS), which demonstrated rapid reversibility upon drug withdrawal alone. A 36-year-old female of East Asian origin with a 12-year history of WD presented with nephrotic syndrome after 21 months of penicillamine therapy. Her 24-h proteinuria was 6.58 g. Her renal biopsy revealed a podocytopathy with early-stage FSGS lesions. Following discontinuation of penicillamine, the proteinuria decreased to 0.04 g/24 h and the nephrotic syndrome reached complete remission in 16 days without corticosteroid therapy. Remission persisted at the 1-year follow-up. This case illustrates that penicillamine can be a cause of reversible nephrotic syndrome secondary to podocytopathy with FSGS lesions and emphasizes the need for early biopsy in unusual proteinuria, with discontinuation of drugs as the main intervention. The clinician should have a high index of suspicion for drug toxicity in patients with WD and nephrotic syndrome, especially if the kidney injury is time-related to penicillamine therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.